Ligaya Prystowsky, MD
Ophthalmology · Nutley, NJNPI 1821071754
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,454 of the $9,694 with a category attached, or 87.2%. It is spread thinly across 25 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations. Among ophthalmology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 191 payments — averaging $50.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$2K
- Eyevance Pharmaceuticals LLC$1K
- Bausch & Lomb Americas Inc.$1K
- NEW World Medical,inc.$910
- Alcon$838
- AbbVie$836
- plus $3K from 19 others
What the payments were for
- Consulting fees$1,20012%
- Speaking & faculty fees$140%
- Food & beverage$8,45487%
- Gifts$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 16 | $1,740 |
| Eyevance Pharmaceuticals LLC | 2 | $1,212 |
| Bausch & Lomb Americas Inc. | 21 | $1,113 |
| NEW World Medical,inc. | 6 | $910 |
| Alcon | 18 | $838 |
| AbbVie(2 entities) | 16 | $836 |
| Sun Pharmaceutical Industries Inc. | 27 | $447 |
| Ivantis, Inc | 20 | $438 |
| Mallinckrodt Hospital Products Inc. | 9 | $337 |
| Nova Eye, Inc. | 3 | $287 |
| Rxsight Inc | 1 | $246 |
| Amgen(2 entities) | 8 | $238 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 11 | $231 |
| Oyster Point Pharma, Inc. | 6 | $222 |
| Aerie Pharmaceuticals, Inc. | 4 | $159 |
| Sight Sciences, Inc. | 9 | $132 |
| Kala Pharmaceuticals, Inc. | 5 | $72 |
| Carl Zeiss Meditec, Inc. | 1 | $65 |
| Carl Zeiss Meditec USA, Inc. | 1 | $60 |
| Biotissue Holdings Inc. | 2 | $25 |
| Haag-streit USA, Inc. | 1 | $25 |
| Dompe US, Inc. | 1 | $17 |
| Harrow Eye, LLC | 1 | $17 |
| Ocular Therapeutix, Inc. | 1 | $14 |
| Notal Vision, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Flarex$1,200
- iDose$416
- DURYSTA$363
- enVista MX60 IOL$272
- Hydrus Microstent$268
- Clareon$248
- MIEBO$248
- XIIDRA$248
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$246
- Rhopressa$241
- Rocklatan$241
- VYZULTA$232
- Voyager DSLT$150
- XEN GLAUCOMA TREATMENT SYSTEM$149
- iStent Trabecular Micro-Bypass System Model iS3$143
- CEQUA$141
- BROMSITE$141
- XELPROS$141
- ACTHAR$135
- TEPEZZA$135
How this compares
$9,694 in reported general payments places this provider in the 90th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TyrvayaVarenicline Tartrate | 140 | $145,509 |
| RestasisCyclosporine | 144 | $142,603 |
| Cyclosporine | 55 | $42,040 |
| XiidraLifitegrast | 36 | $36,856 |
| MieboPerfluorohexyloctane/Pf | 35 | $33,931 |
| LumiganBimatoprost | 54 | $26,300 |
| VevyeCyclosporine | 18 | $22,947 |
| VyzultaLatanoprostene Bunod | 41 | $19,971 |
| ProlensaBromfenac Sodium | 32 | $10,977 |
| RocklatanNetarsudil Mesylat/Latanoprost | 22 | $10,004 |
| Alphagan PBrimonidine Tartrate | 19 | $9,350 |
| Lotemax SmLoteprednol Etabonate | 35 | $8,607 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 31 | $7,069 |
| Brimonidine Tartrate | 111 | $4,861 |
| Bromfenac Sodium | 20 | $4,521 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P | $836 | $178,254217 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $222 | $145,509140 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $1,113 | $90,758112 claims |
| Harrow Eye, LLCVevye | $17 | $22,94718 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm | $231 | $19,58467 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $159 | $10,00422 claims |
| AlconSimbrinza | $838 | $7,06931 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Nutley
- Jai ParekhWoodland Park$2M
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Cynthia MatossianPennington$655K
- Eric MannDover$604K
- Brett BieloryRutherford$477K
- Albert KhouriNewark$428K
- Robert FechtnerNewark$324K
- Rajen DesaiFreehold$311K
- Douglas GraysonIselin$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.